Clinical Trends for June 2017

Ryan Syrek


June 30, 2017

Clinical Trend of the Week (June 17-23): CANVAS Trial

Results of a highly anticipated study are responsible for this week's top search term. Findings from the Canagliflozin Cardiovascular Assessment Study (CANVAS) and the CANVAS renal-end-points trial were presented at the American Diabetes Association (ADA) 2017 Scientific Sessions and published in the New England Journal of Medicine. The results revealed reduced cardiovascular events and a decreased rate of renal decline among participants, two-thirds of whom had established cardiovascular disease. However, the risk for lower-limb amputation doubled. Canagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. Further investigations may be necessary to conclude whether the benefits and risks are class effects. As more findings become available, similar searches to this week's top term are likely to grow in popularity.

For more information on the use of canagliflozin, read here.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.